Genital irritation is common but often misunderstood. From infections to hygiene habits and hormonal shifts, experts explain ...
Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV ...
Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical ...
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
Awareness Month. The purpose is to promote knowledge about the impact of STIs, reduce stigma and promote testing and ...
GOT an itch in your britches? It happens to the best of us. We’ve all had to get creative with calming a tickle in our crotch ...
GOT an itch in your britches? It happens to the best of us. We’ve all had to get creative with calming a tickle in our crotch ...
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
You can’t get shingles in your 20s,” her mom told her. Still, Pipps went to her dad for a second opinion. “My dad took one ...
STD Diagnostics Market OutlookThe global STD diagnostics market is projected to grow at a CAGR of 7–8% during the forecast period, driven by the rising burden of sexually transmitted diseases ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results